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1.56, P  0.001) than it was for patients in the highest quintileHealth-related quality of life as a predictor of mortality and hos-
level. The adjusted relative risk values of mortality per 10-pitalization: The Dialysis Outcomes and Practice Patterns Study
point lower HRQOL score were 1.13 for MCS, 1.25 for PCS,(DOPPS).
and 1.11 for KDCS. The corresponding adjusted values for RRBackground. We investigated whether indicators of health-
for first hospitalization were 1.06 for MCS, 1.15 for PCS, andrelated quality of life (HRQOL) may predict the risk of death
1.07 for KDCS. Each RR differed significantly from 1 (P and hospitalization among hemodialysis patients treated in
0.001). For 1 g/dL lower serum albumin concentration, the RRseven countries, taking into account serum albumin concentra-
of death adjusted for PCS, MCS, and KDCS and the othertion and several other risk factors for death and hospitalization.
covariates was 1.17 (P  0.01). Albumin was not significantlyWe also compared HRQOL measures with serum albumin
associated with hospitalization (RR  1.03, P  0.5).regarding their power to predict outcomes.
Conclusion. Lower scores for the three major componentsMethods. We analyzed data from the Dialysis Outcomes and
of HRQOL were strongly associated with higher risk of deathPractice Patterns Study (DOPPS), an international, prospec-
and hospitalization in hemodialysis patients, independent of ative, observational study of randomly selected hemodialysis
series of demographic and comorbid factors. A 10-point lowerpatients in the United States (148 facilities), five European
PCS score was associated with higher elevation in the adjustedcountries (101 facilities), and Japan (65 facilities). The total
mortality risk, as was a 1 g/dL lower serum albumin level. Moresample size was composed of 17,236 patients. Using the Kidney
research is needed to assess whether interventions to improveDisease Quality of Life Short Form (KDQOL-SFTM), we deter-
quality of life lower these risks among hemodialysis patients.mined scores for three components of HRQOL: (1) physical
component summary (PCS), (2) mental component summary
(MCS), and (3) kidney disease component summary (KDCS).
Complete responses on HRQOL measures were obtained from The concept of health-related quality of life (HRQOL)10,030 patients. Cox models were used to assess associations
takes into account patient well-being as expressed bybetween HRQOL and the risk of death and hospitalization,
both the physical and psychologic (or mental) domainsadjusted for multiple sociodemographic variables, comorbidi-
ties, and laboratory factors. of health. HRQOL may be affected by several factors,
Results. For patients in the lowest quintile of PCS, the ad- including the clinical manifestations of diseases, the side
justed risk (RR) of death was 93% higher (RR  1.93, P  effects of treatments, and the quality of the relationships0.001) and the risk of hospitalization was 56% higher (RR 
of the patient with family members and health care pro-
viders [1]. In addition to providing information about
individual well-being at a given moment, the assessmentKey words: DOPPS, end-stage renal disease (ESRD), hemodialysis,
hospitalization, mortality, quality of life. of HRQOL may help identify an individual’s risk for
certain outcomes. Impaired quality of life may be a causeReceived for publication July 4, 2002
or a marker of developing cardiovascular disorders andand in revised form December 12, 2002, and February 20, 2003
Accepted for publication March 4, 2003 other important outcomes, such as death and hospitaliza-
tion [2–5]. 2003 by the International Society of Nephrology
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There is evidence that HRQOL predicts outcomes for MCS and PCS were derived from eight different
among hemodialysis patients [6, 7]. A study of 1000 pa- subscales, originally developed for the SF-36 Short-Form
tients at three dialysis facilities in the United States re- Health Survey (SF-36): (1) physical functioning, (2) role-
ported an association between lower scores in the physi- physical, (3) bodily pain, (4) general health, (5) vitality,
cal component of quality of life and higher risk of death (6) social functioning, (7) role-emotional, and (8) mental
and hospitalization at least until the next 24 months [6]. health [12].
A larger study, involving 5256 patients at 243 dialysis The questions used for the KDCS are not part of the
facilities in the United States and Europe, presented SF-36. They were included in the KDQOL-SF to take
evidence that the psychologic or mental components of into account particular health-related concerns of indi-
quality of life predict death and hospitalization in hemo- viduals with kidney diseases and end-stage renal disease
dialysis patients [8]. Self-reported depression, as assessed (ESRD) patients treated by dialysis [9]. The scale for
by questions from the mental health scale of the Kidney the KDCS was derived by 11 subscales [9]: (1) symptoms/
Disease and Quality of Life Short Form (KDQOL-SFTM) problems (muscle soreness, chest pain, cramps, itchy
[9], was significantly associated with a higher risk of death skin, shortness of breath, faintness or dizziness, lack of
and hospitalization, even after taking into account serum appetite, and problems with vascular access), (2) effects
albumin concentration and several other risk factors. of kidney disease on daily life, (3) burden of kidney
This study provides additional evidence of the rela- disease, (4) work status, (5) cognitive function, (6) qual-
tionships between HRQOL and hemodialysis outcomes. ity of social interaction, (7) sexual function, (8) sleep,
It was developed to verify whether different components (9) social support, (10) dialysis staff encouragement, and
of HRQOL are associated with the risks of death and (11) patient satisfaction. Because of the weighting used,
hospitalization among hemodialysis patients. We also the scales of the PCS ranged from 1.73 to 76.28 and
compared HRQOL and serum albumin regarding pre- the MCS scales ranged from 1.27 to 80.74. For KDCS,
dictive power for death and hospitalization. the scales ranged from 0 to 100.
Statistical methodsMETHODS
All analyses were performed within the populationThe data used for the analysis were from the Dialysis
groups (United States, Europe, and Japan) as well asOutcomes and Practice Patterns Study (DOPPS), an in-
overall. Cox models were used to estimate the relativeternational, prospective, observational study of hemodi-
risk (RR) of the two patient outcomes (death and firstalysis practice patterns and associated outcomes [10, 11].
hospitalization after initiation of the study) for every 10-Nationally representative samples of dialysis facilities were
point lower score of each of the three quality-of-liferecruited in five European countries (France, Germany,
components and their subscales. In one set of models,Italy, Spain, and the United Kingdom), Japan, and the
all patients were included, independent of the durationUnited States. Within each participating facility, study
of the follow-up. For the other two sets of models, restric-patients were randomly selected, and, within each coun-
tions were made based on duration of follow-up in ordertry, the appropriate Institutional Review Boards approved
to evaluate the disjoint short-term versus long-term ef-the study. Informed patient consent was obtained in ac-
fects. One set looked at follow-up censored at 6 months;cordance with local requirements. The overall design of
the other set considered only patients with follow-up6the DOPPS has been published previously [10].
months. Models were developed to assess the associationThe present study included data from 148 facilities in
between HRQOL and outcomes in subgroups as definedthe United States, 101 facilities in Europe, and 65 facili-
by age (60 years versus 60 years), region (Unitedties in Japan, with a total sample size of 17,236 patients
States, Europe, and Japan), time on dialysis at study(10,030 with complete information on HRQOL mea-
start (3 months or less, 4 months to less than 1 year, 1sures). The data regarding HRQOL, sociodemographic
year to less than 2 years, and 2 or more years), and serumfactors, comorbidities, laboratory values, and treatment
albumin level (3.5 g/dL, 3.5 to 3.9 g/dL, and 4 g/dL).factors were collected at patient entry into the study.
Cox adjusted RR values for death and hospitalizationData collection began in 1997 in the United States, 1998
were estimated by comparing quintiles of HRQOL scores,in Europe, and 1999 in Japan. Patients were replaced
using the highest quintile as referent. Similar modelsas they left participating facilities for reasons of death,
were used to assess the RR of death and hospitalizationtransplantation, change in treatment modality, with-
by quintiles of albumin. Missing data were handled withdrawal from dialysis, recovery of renal function, or trans-
indicator variables.fer to another facility.
The models were stratified by country of hemodialysisThe patient responses to the KDQOL-SF were used
treatment and diabetes and adjusted for age, gender,to determine scores of the kidney disease component sum-
socioeconomic factors, body mass index (BMI), predial-mary (KDCS), the mental component summary (MCS)
and the physical component summary (PCS). The scales ysis systolic blood pressure, treatment with epoetin, dial-
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ysis dose by the equilibrated Kt/V (eKt/V) [13], type of Comparisons of death and hospitalization risks by
vascular access, laboratory tests, comorbidities, and time patient response to the KDQOL-SF
on dialysis [14]. The following laboratory factors and co- We also compared patients who answered all ques-
morbidities were included in the Cox models: predialysis tions on the KDQOL-SF (N  10,030) with those pa-
serum albumin, creatinine, phosphorus and hemoglobin tients who provided an incomplete response or no re-
concentrations, normalized protein catabolic rate (nPCR), sponse (N 7206). For the latter group, the risk of death
coronary artery disease, congestive heart failure, other was more than two times higher (RR  2.51, 95% CI 
cardiac disorders (cardiac arrest, arrhythmia, permanent 2.35 to 2.69, P  0.001) and the risk of hospitalization
pacemaker, pericarditis, prosthetic heart valve), hyper- was 33% higher (RR  1.33, 95% CI  1.26 to 1.41,
tension, cerebrovascular disease, peripheral vascular dis- P  0.001) compared with patients who responded to
ease, diabetes mellitus, lung disease, cancer (excluding all items. These associations remained statistically sig-
skin cancer), infection with the human immunodefi- nificant even after adjustment for sociodemographic
ciency virus or AIDS, gastrointestinal bleeding, neuro- variables, laboratory values, comorbidities, treatment
logic disease (seizure, dementia, organic brain syndrome, factors, time on dialysis, and country. The adjusted risk
Parkinson’s disease), psychiatric disease, recurrent cellu- of death was 40% higher for patients who did not com-
litis, and dyspnea. The following socioeconomic variables plete all items of the questionnaire than for those who
were included in the regression models: living status (liv- did (RR  1.40, 95% CI  1.29 to 1.51, P  0.001). The
ing alone, living with family/friends, living in nursing adjusted risk of hospitalization was estimated as 12%
home, homeless/prisoner), marital status (married or not), higher for those who did not respond to all questions on
education (high school or lower grade, attended college), the KDQOL questionnaire (RR  1.12, 95% CI  1.04
employment status (for ages 18 to 60 years), and yearly to 1.20, P  0.003).
household income (less than $5,000; $5,001 to $10,000;
$10,001 to $20,000; $20,001 to $40,000; $40,001 to $75,000 Relative risks of death and hospitalization per 10-point
and more than $75,000). Equivalent income categories lower HRQOL score and 1 g/dL lower serum
were provided on the European and Japanese question- albumin concentration
naires based on United States monetary exchange rates
As shown in Table 3, HRQOL was found to be signifi-in 1998 for Europe, and exchange rates in 1999 for Japan.
cantly associated with the risk of death and hospitaliza-All statistical analyses were performed using SAS soft-
tion (P 0.001). The increase in the unadjusted mortalityware, version 8 [15].
risk for each 10-point lower HRQOL score was 47% for
PCS (RR  1.47; 95% CI  1.41 to 1.54), 16% for MCS
RESULTS (RR 1.16; 95% CI 1.12 to 1.21), and 15% for KDCS
(RR  1.15; 95% CI  1.11 to 1.18). For each 10-pointBaseline characteristics
lower HRQOL score, the mortality risk (stratified byAmong 17,236 patients included in DOPPS, 10,030
country and diabetes and adjusted for the covariates(58.2%) completed all the questions of the KDQOL-SF.
listed in Table 1) increased 25% for the PCS (RR  1.25;The percentages of patients with complete responses to
95% CI  1.20 to 1.30), 13% for the MCS (RR  1.13;the KDQOL-SF in Europe, Japan, and the United States
95% CI  1.09 to 1.17), and 11% for KDCS (RR were, respectively, 74.8% (N 4591), 68.5% (N 2784),
1.11; 95% CI  1.08 to 1.13). For hospitalization, theand 47.6% (N 9861). Tables 1 and 2 show the distribu-
unadjusted RR values for each 10-point lower HRQOLtion, within the DOPPS sample, of baseline characteris-
score were 1.25 (95% CI  1.21 to 1.28) for PCS, 1.09tics that were used in the adjusted Cox models, both for
(95% CI  1.07 to 1.11) for MCS, and 1.10 (95% CI the whole sample and stratified by patients with complete
1.08 to 1.13) for KDCS. The adjusted RR values wereor incomplete response to the KDQOL-SF. In the whole
1.15 (95% CI  1.12 to 1.19) for PCS, 1.06 (95% CI sample, the mean age of the patients was 60.5  15.2
1.04 to 1.08) for MCS, and 1.07 (95% CI  1.05 to 1.09)years. Males were 57.4% of the sample. Approximately
for KDCS.half of the patients were receiving dialysis for less than
The associations between HRQOL and outcomes1 year, 38% had diabetes mellitus, and 21% were re-
were stronger in Japan than in Euro-DOPPS or theported as having psychiatric disorders. Patients who did
United States, with the highest RR observed for PCSnot complete all items of the KDQOL-SF were signifi-
(Table 3). The adjusted RR for the association betweencantly older (P 0.001) and had lower levels of albumin,
PCS and mortality was approximately 37% higher increatinine, hemoglobin, and nPCR. These patients also
Japan than the United States and 33% higher in Japanhad a significantly shorter time on dialysis therapy (P 
than Euro-DOPPS. In Japan, the adjusted RR of hospi-0.001), lower levels of BMI, lower predialysis systolic
talization related to PCS was approximately 22% higherblood pressure, lower eKt/V, and higher prevalence of
several comorbidities. compared with the United States and 12% higher com-
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Table 1. Sociodemographic variables and years on dialysis at study starta
Filled out entire KDQOL-SF
All Yes No
(N  17,236) (N  10,030) (N  7206) P value
Age years 60.515.2 58.914.9 62.815.3 0.0001
Male 57.4 57.6 56.9 0.5885
Median years on dialysis 1.04 1.48 0.43 0.0001
Socioeconomic factorsb
Yearly incomec 0.0001
$5000 13.9 13.6 16.8
$5001–$10,000 26.3 26.3 27.8
$10,001–$20,000 27.5 27.6 27.5
$20,001–$40,000 21.6 21.9 20.2
$40,001–$75,000 7.9 7.9 8.1
$75,000 2.8 2.7 3.5
Education 0.0001
High school or less 60.0 63.9 54.2
Attended college 40.0 36.1 45.8
Occupational status 0.0001
Employed 17.2 20.2 11.9
Retired 38.5 36.8 41.4
Disabled 18.9 17.1 22.2
Unemployed 9.8 9.2 10.9
Homemaker, never employed 15.5 16.7 13.6
Living status 0.0001
Living alone 14.8 14.7 14.9
Living with family/friends 79.2 82.0 75.0
Living in nursing home 5.7 3.1 9.7
Homeless/prisoner 0.3 0.2 0.3
KDQOL-SF is Kidney Disease Quality of Life-Short Form.
a Results are represented by the meanSD or %, unless specified to be median. The yes column indicates the sample used for the analysis.
b Data on income, education, occupational status, and social support indicators were unknown or missing for 57.8%, 5.0%, 23.7%, and 4.1% of the patients,
respectively
c Yearly income was collected on the same patient questionnaire on which quality of life was based. These percentages represent the patients who completed this
part, but not the entire patient questionnaire.
pared with Euro-DOPPS. The PCS scores were also sig- (not adjusted for HRQOL measures) RRs of death and
nificantly higher among patients from Japan than those hospitalization per 1 g/dL lower concentration of serum
from Euro-DOPPS and the United States (P  0.001). albumin were 1.20 (95% CI  1.08 to 1.33) and 1.08
The associations between HRQOL scores and the two (95% CI  1.00 to 1.16), respectively. Among patients
outcomes, death and hospitalization, were similar in the who did not complete the KDQOL-SF, the lower level
United States and Euro-DOPPS. of albumin was significantly associated with death (P 
Table 3 also shows the RRs of death and hospitaliza- 0.001) and hospitalization (P  0.003); in this group of
tion per 1 g/dL lower concentration of serum albumin, nonrespondents to the KDQOL-SF, the RR per 1 g/dL
using Cox models adjusted for the variables listed in Ta- lower concentration of albumin was 1.22 (95% CI 1.11
bles 1 and 2 and all three summary measures of HRQOL to 1.35) for death and 1.12 (95% CI  1.04 to 1.22) for
(PCS, MCS, and KDCS). As observed for the HRQOL hospitalization (these results are not shown in the table).
summary measures, the associations between albumin The RRs of the associations between albumin level and
and adverse outcomes were stronger in Japan than in outcomes (death and hospitalization) did not differ sig-
the other treatment locations. A 10-point lower PCS was nificantly between patients who completed all questions
associated with similar or higher elevation in the adjusted
of the KDQOL-SF and those who did not (P  0.1).
mortality risk, as was a 1 g/dL lower serum albumin
The associations of lower HRQOL scores with higherlevel. Albumin was not significantly associated with the
risks of death and hospitalization were not significantlyadjusted risk of hospitalization in models that included
different between patients younger than 60 years of ageall three HRQOL summary measures.
and those 60 years or older. Likewise, adjusted RR val-In models adjusted for all variables listed in Tables 1
ues did not differ significantly among those with serumand 2, but not for HRQOL measures, a lower level of
albumin 3.5 g/dL, 3.5 to 3.9 g/dL, and 4 g/dL. Simi-albumin was significantly (P  0.001) associated with a
larly, the adjusted associations between HRQOL andhigher risk of death and marginally significantly associ-
outcomes did not vary significantly by time on dialysis:ated with hospitalization (P 0.05) among patients who
3 months, 4 months to less than 1 year, 1 year to lesshave completed the KDQOL-SF. Among this same
group of respondents to the KDQOL-SF, the adjusted than 2 years, and 2 or more years (data not shown).
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Table 2. Treatment, laboratory and comorbidity factors at study starta
Filled out entire KDQOL-SF
All Yes No
(N  17,236) (N  10,030) (N  7,206) P value
Albumin g/dLb 3.60.6 3.70.5 3.50.6 0.0001
Creatinine mg/dLb 9.13.4 9.53.3 8.43.5 0.0001
Phosphorus mg/dLb 5.71.9 5.85.6 5.62.0 0.0001
Hemoglobin g/dLb 10.21.7 10.31.7 10.21.7 0.0001
Epoetin U/kg/week 162123 147115 185131 0.0001
Predialysis systolic blood pressure mm Hg 15026 15125 14926 0.0001
Body mass index 24.05.4 24.05.3 24.15.5 0.0001
eKt/V 1.190.29 1.200.28 1.170.29 0.0126
nPCR 1.030.28 1.040.28 0.990.97 0.0001
Coronary heart disease 38.3 34.4 43.7 0.0001
Congestive heart failure 33.8 29.5 39.9 0.0001
Other cardiac disorders 30.8 29.8 32.3 0.0007
Hypertension 75.3 76.1 74.2 0.0001
Cerebrovascular disease 16.1 13.4 19.8 0.0001
Peripheral vasculopathy 22.0 19.5 25.6 0.0001
Diabetes mellitus 37.8 33.9 43.0 0.0001
Lung disease 10.7 9.3 12.6 0.0001
Cancer, excluding skin 9.8 8.9 11.1 0.0003
HIV 0.8 0.6 1.1 0.0403
Gastrointestinal bleeding 7.0 5.9 8.5 0.0001
Neurologic disease 8.4 6.5 11.0 0.0001
Psychiatric disease 20.9 18.9 23.8 0.0001
Recurrent cellulitis 7.3 5.9 9.2 0.0001
Dyspnea 25.3 22.1 29.7 0.0001
Type of vascular access 0.0001
Fistula 54.7 62.5 42.1
Graft 24.0 22.1 27.0
Permanent catheter 12.0 8.6 17.4
Temporary catheter 9.3 6.8 13.4
Abbreviations are: eKt/V, equilibrated Kt/V; nPCR, normalized protein catabolic rate; HIV, seropositive for the human immunodeficiency virus; KDQOL-SF,
Kidney Disease Quality of Life-Short Form.
aResults are represented by the mean  SD or %
bValues are predialysis at study start
Table 3. Relative risk (RR) of death and hospitalization per 10-point lower HRQOL score and 1 g/dL lower serum albumin concentration,
by total group and treatment location
RR of death (95% CI) RR of hospitalization (95% CI)
HRQOL
measure MeanSD Unadjusted Adjusted Unadjusted Adjusted
Total group
MCS 44.911.9 1.16 (1.12–1.21)c 1.13 (1.09–1.17)c 1.09 (1.07–1.11)c 1.06 (1.04–1.08)c
PCS 35.310.8 1.47 (1.41–1.54)c 1.25 (1.20–1.30)c 1.25 (1.21–1.28)c 1.15 (1.12–1.19)c
KDCS 63.513.0 1.15 (1.11–1.18)c 1.11 (1.08–1.15)c 1.10 (1.08–1.13)c 1.07 (1.05–1.09)c
Albumin 3.640.57 1.43 (1.31–1.57)c 1.17 (1.05–1.30)b 1.23 (1.15–1.32)c 1.03 (0.95–1.11)
Europe
MCS 42.711.8 1.15 (1.07–1.24)c 1.09 (1.02–1.17)a 1.08 (1.04–1.13)c 1.04 (1.00–1.08)
PCS 35.510.5 1.60 (1.46–1.74)c 1.24 (1.13–1.37)c 1.28 (1.22–1.34)c 1.19 (1.13–1.25)c
KDCS 62.812.5 1.17 (1.11–1.24)c 1.10 (1.03–1.17)b 1.11 (1.07–1.15)c 1.06 (1.02–1.11)b
Albumin 3.840.59 1.50 (1.25–1.80)c 1.23 (0.98–1.54) 1.26 (1.12–1.42)c 1.06 (0.95–1.20)
Japan
MCS 44.511.5 1.34 (1.07–1.67)b 1.14 (0.92–1.43) 1.16 (1.09–1.24)c 1.08 (1.02–1.14)b
PCS 41.79.0 2.36 (1.91–2.93)c 1.66 (1.27–2.16)c 1.55 (1.41–1.69)c 1.33 (1.21–1.47)c
KDCS 65.511.8 1.47 (1.22–1.76)c 1.24 (1.02–1.51)a 1.24 (1.17–1.32)c 1.13 (1.06–1.21)c
Albumin 3.770.43 2.96 (1.87–4.68)c 1.43 (0.80–2.54) 1.67 (1.24–2.25)c 1.19 (0.88–1.61)
United States
MCS 46.511.8 1.16 (1.11–1.21)c 1.13 (1.08–1.17)c 1.08 (1.05–1.11)c 1.05 (1.02–1.08)c
PCS 32.710.6 1.41 (1.34–1.48)c 1.21 (1.16–1.27)c 1.17 (1.13–1.21)c 1.09 (1.04–1.13)c
KDCS 63.213.7 1.13 (1.09–1.16)c 1.10 (1.06–1.14)c 1.07 (1.04–1.10)c 1.05 (1.02–1.08)b
Albumin 3.540.56 1.41 (1.28–1.55)c 1.16 (1.02–1.31)a 1.18 (1.08–1.28)c 0.99 (0.90–1.09)
Abbreviations are: HRQOL, health-related quality of life; MCS, mental component summary; PCS, physical component summary; KDCS, kidney disease component
summary; CI, confidence interval.
aP  0.05
bP  0.01
cP  0.001
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Table 4. Adjusteda relative risk (RR) of death and hospitalization per 10-point lower score for PCS, MCS, and KDCS, with all three
health-related summary measures of HRQOL in the Cox models
RR of death (95% CI) RR of hospitalization (95% CI)
Not adjusted for Adjusted for Not adjusted for Adjusted for
HRQOL measure albumin albumin albumin albumin
PCS 1.29 (1.23–1.35)c 1.29 (1.23–1.35)c 1.15 (1.11–1.19)c 1.15 (1.11–1.18)c
MCS 1.13 (1.08–1.18)c 1.13 (1.08–1.18)c 1.05 (1.02–1.08)c 1.05 (1.02–1.08)b
KDCS 0.98 (0.94–1.02) 0.98 (0.94–1.02) 1.00 (0.97–1.03) 1.00 (0.97–1.03)
Abbreviations are: HRQOL, health-related quality of life; MCS, mental component summary; PCS, physical component summary; KDCS, kidney disease component
summary; CI, confidence interval.
a All Cox models were adjusted for the summary measures of HRQOL and the variables listed in Tables 1 and 2
bP  0.01
cP  0.001
Associations between HRQOL and outcomes, The inclusion of albumin in the Cox models that in-
cluded all three HRQOL summary measures did notrestricted by follow-up duration
change the RRs of death and hospitalization (Table 4).In the models restricted to patients censored at 6
In these models, PCS and MCS remained significantlymonths and patients with more than 6 months of follow-
associated with death and hospitalization and no associa-up, RR values were similar to values in the unrestricted
tion was observed between KDCS and the outcomes.models (Table 3), for both death and hospitalization.
By contrast, KDCS was significantly associated with mor-For each 10-point reduction in score in the 6-month
tality risk in models where it was included with only onecensored models, the adjusted RR values for death were
other indicator of HRQOL (either PCS or MCS). KDCS1.33 (95% CI  1.23 to 1.43) for PCS, 1.17 (95% CI 
was also significantly associated with hospitalization in1.09 to 1.25) for MCS, and 1.15 (95% CI  1.08 to 1.22)
the model that included PCS but not in the model thatfor KDCS. For hospitalization, the corresponding values
included MCS.of RR for PCS, MCS and KDCS were 1.18 (95% CI 
1.14 to 1.23), 1.08 (95% CI  1.05 to 1.12), and 1.08
Adjusted relative risks of death and hospitalization for(95% CI  1.05 to 1.11), respectively. Each RR value
KDQOL-SF subscaleswas statistically significant for P  0.001. In the models
Table 5 shows the adjusted RR of death and hospital-restricted by 6 months of follow-up, the adjusted RR
ization for every 10-point lower HRQOL score for the 19values for death were 1.26 (95% CI  1.20 to 1.32, P 
subscales of the KDQOL-SF. Each of the eight subscales0.001) for PCS, 1.14 (95% CI  1.10 to 1.19, P  0.001)
that make up PCS and MCS scores were significantly andfor MCS, and 1.12 (95% CI  1.08 to 1.16, P  0.001)
independently associated with death and hospitalizationfor KDCS. For hospitalization the corresponding RR
(P 0.05). The adjusted RR per 10-point lower HRQOLvalues for PCS, MCS, and KDCS were 1.13 (95% CI 
score varied from 1.02 to 1.10. For the KDCS, the follow-1.08 to 1.17, P  0.001), 1.04 (95% CI  1.00 to 1.07),
ing subscales were significantly and independently asso-and 1.07 (95% CI  1.04 to 1.11), respectively.
ciated with both mortality and hospitalization: symp-
Associations between HRQOL and outcomes with the toms/problems, effects of kidney disease on daily life,
inclusion of more than one summary measure in the burden of kidney disease, work status, cognitive function,
Cox models, with and without the inclusion of albumin quality of social interaction, and sleep. Diminished sex-
ual function, social support, and dialysis staff encourage-In Cox models adjusted for all variables listed in Ta-
ment were significantly associated with risk of mortalitybles 1 and 2 (except albumin), and with the inclusion of
but not of hospitalization. Patient satisfaction was notall three summary measures of HRQOL (MCS, PCS, and
independently associated with either mortality or hospi-KDCS), both PCS and MCS were significantly related to
talization.death and hospitalization (Table 4). For every 10-point
lower PCS score, the risk of death increased by 29%
Associations between HRQOL components (by(RR  1.29; 95% CI  1.23 to 1.35, P  0.001) and the
quintiles) and outcomes, adjusted for albuminrisk of hospitalization increased by 15% (RR 1.15; 95%
Figure 1 shows the RRs for associations betweenCI  1.11 to 1.19, P  0.001). The RRs of death and
HRQOL and the risk of mortality and hospitalizationhospitalization related to 10-point lower MCS score were
by quintiles of the scores of each HRQOL component,1.13 (95% CI  1.09 to 1.18, P  0.001) and 1.05 (95%
adjusted for the variables listed in Tables 1 and 2, includ-CI  1.02 to 1.08, P  0.002), respectively. Significant
ing albumin. The highest quintile was used as reference.associations with outcomes were not observed for KDCS
in models simultaneously adjusted for MCS and PCS. Both mortality and hospitalization increased significantly
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Table 5. Adjusted relative risk (RR) of death and hospitalization per 10-point lower scores for mental component summary (MCS), physical
component summary (PCS), and kidney disease component summary (KDCS) subscales
RR of death RR of hospitalization
Subscales (95% CI) (95% CI)
For the physical and mental component summaries
Physical functioning 1.10 (1.08–1.11)c 1.05 (1.04–1.06)c
Role—physical 1.03 (1.02–1.05)c 1.02 (1.02–1.03)c
Bodily pain 1.06 (1.04–1.08)c 1.05 (1.04–1.06)c
General health 1.10 (1.07–1.12)c 1.05 (1.04–1.07)c
Vitality 1.09 (1.07–1.12)c 1.05 (1.04–1.06)c
Social functioning 1.07 (1.05–1.09)c 1.03 (1.02–1.04)c
Role—emotional 1.03 (1.02–1.04)c 1.02 (1.01–1.03)c
Mental health 1.07 (1.05–1.09)c 1.04 (1.03–1.06)c
For the kidney disease component summary
Symptoms/problems 1.08 (1.05–1.10)c 1.07 (1.06–1.09)c
Effects of kidney disease on daily life 1.05 (1.03–1.07)c 1.04 (1.02–1.05)c
Burden of kidney disease 1.04 (1.02–1.05)c 1.03 (1.01–1.04)c
Work status 1.02 (1.00–1.04)a 1.02 (1.01–1.03)c
Cognitive function 1.05 (1.03–1.08)c 1.02 (1.01–1.04)b
Quality of social interaction 1.03 (1.01–1.05)b 1.03 (1.01–1.04)b
Sexual function 1.02 (1.00–1.04)a 1.01 (1.00–1.02)
Sleep 1.05 (1.03–1.07)c 1.04 (1.02–1.05)c
Social support 1.02 (1.00–1.03)b 1.00 (0.99–1.01)
Dialysis staff encouragement 1.02 (1.01–1.04)b 1.01 (1.00–1.02)
Patient satisfaction 1.01 (0.99–1.03) 1.00 (0.99–1.02)
aP  0.05; bP  0.01; cP  0.001
from the highest to the lowest quintiles of the HRQOL of the KDQOL-SF (i.e., MCS, PCS, and KDCS). These
component scores (P values for trend 0.001). For the associations remained statistically significant after ad-
PCS score, the adjusted risk of death was 93% higher justment for several risk factors of death or hospitaliza-
(RR  1.93) for patients in the lowest quintile (scores tion, including serum albumin concentration, sociodemo-
25) compared with the highest quintile (scores 46). graphic characteristics, years on dialysis, type of vascular
The adjusted risk of hospitalization was 56% higher (RR access, several comorbidities, and treatment factors
1.56) when comparing patients in the lowest and highest [16–19]. Moreover, the adjusted associations between
quintiles. HRQOL and outcomes were similar among several sub-
groups, as defined by age (60 years versus 60 years),
Adjusted relative risk of adverse outcome by quintiles albumin levels (3.5 g/dL, 3.5 to 3.9 g/dL, and 4 g/dL),
of albumin and HRQOL summary measures, without
and time on dialysis (3 months or less, 4 months to less
adjustment for albumin
than 1 year, 1 year to less than 2 years, and 2 or more
Figure 2 displays Cox-adjusted RR values of death and years). It should be noted, however, that the association
hospitalization by quintiles of each of the three HRQOL between HRQOL and death was much stronger than
components and albumin, using the highest quintile as the associations between HRQOL and hospitalization.
the referent category. Table 6 shows the range values of The adjusted associations between lower PCS score
the quintiles and RR with the respective 95% CIs that and higher risks of death and hospitalization differed
were used for Figure 2. Only the data regarding patients by treatment location, being stronger in Japan than in
with complete information for albumin and HRQOL Europe or the United States. The HRQOL scores varied
were included in these Cox models. The RR values for less within Japan than within Europe or the United
the HRQOL components were adjusted for all covari-
States. Thus, it is possible that a 10-point decrement
ates, except for albumin. PCS was the variable most
represents a more profound deterioration of quality ofstrongly associated with both mortality and hospitaliza-
life among Japanese patients and hence is associatedtion.
with increased risk of adverse outcomes. It is important
to assess whether variation in access to health care and
DISCUSSION in quality of care across dialysis facilities within each
region (i.e., Japan, United States, and Europe) influencesThis large international study shows highly significant
these findings.associations between lower HRQOL scores and higher
PCS was the HRQOL component most strongly asso-risk of death and hospitalization among hemodialysis
ciated with both death and hospitalization. Patients inpatients. These inverse associations between HRQOL
and outcomes were observed for all three components the lowest quintile of PCS had 93% higher adjusted risk
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Fig. 2. Adjusted relative risks of death (A) and first hospitalization
(B) by quintile of scores for each component of health-related quality
of life (HRQOL) and for albumin, using the highest quintile as the
reference group. For all eight lines, there was a statistically significant
trend (each P  0.001, except for hospitalization and albumin, which
were P  0.05) for the risks of both outcomes to increase with lower
scores. Abbreviations are: MCS, mental component summary; PCS,
physical component summary; and KDCS, kidney disease component
summary.
Fig. 1. Relative risks of death () and first hospitalization () by subscales used for MCS and PCS were significantly asso-
quintile of scores for each component of health-related quality of life ciated with the outcomes. The effects of MCS and PCS(HRQOL), adjusted for all variables in Tables 1 and 2, including albu-
were also independent of the KDCS and albumin. Inmin, stratified by country and diabetes. The highest quintile is used as
the reference group. For all six lines, there was a statistically significant fact, the increase in the mortality and hospitalization
trend (each P  0.001) for the risks of both outcomes to increase with risks related to lower scores in MCS and PCS did notlower scores. (A ) Physical component summary (PCS). (B ) Mental
change when albumin was included in Cox models thatcomponent summary (MCS). (C ) Kidney disease component summary
(KDCS). contained all three summary measures of HRQOL and
the variables included in Table 1 and Table 2. It is also
important to note that even though KDCS, like MCS and
PCS, predicts death and hospitalization independently ofof death and 56% higher adjusted risk of hospitalization
albumin, no association is observed between KDCS andwhen compared with those in the highest quintile. This
outcomes in models that contain MCS and PCS. Thesefinding is consistent with a previous investigation that
results indicate that KDCS and albumin contribute littlehas shown a stronger effect of PCS on death and hospital-
to predictions of death and hospitalization when infor-ization as compared with MCS [6]. It should be noted,
mation about PCS and MCS is available.however, that the effects of MCS on the two outcomes
were independent of PCS and vice versa. Moreover, all Several studies have shown that albumin is one of the
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strongest predictors of adverse outcomes, particularly
death, in dialysis patients [17, 20]. Consistent with these
previous observations, our study showed a strong associ-
ation between low albumin and higher risk of death. Simi-
lar to HRQOL summary score, albumin level was less
strongly associated with risk of hospitalization than with
risk of death. De Oreo [6], in his study of HRQOL and
dialysis outcomes, also found a much stronger associa-
tion of albumin with mortality risk than with hospitaliza-
tion (measured as hospital days). The reasons for a
weaker association of both albumin and HRQOL with
hospitalization are not clear, although they may be partly
related to the complex interplay of factors that influence
the decision for hospital admission. Local treatment or
hospitalization policies and patient or family prefer-
ences, for instance, are factors that may influence hospi-
talization [21–25].
It is important to note that, according to the results
of this study, the associations between lower HRQOL
score and higher risk of death and hospitalization are not
confounded by albumin. The comparisons by quintiles of
albumin and by quintiles of HRQOL scores support the
conclusion that MCS, PCS, and KDCS are at least as
powerful as albumin in predicting death and hospitaliza-
tion. Moreover, by treating HRQOL scores as a continu-
ous variable, we showed that a 10-point lower PCS score
was associated with a rise in mortality risk that was simi-
lar to (or even greater than) the risk associated with
a 1 g/dL lower serum albumin level. This finding was
observed in Europe, Japan, and the United States. It is
important to note that the standard deviations of PCS
and albumin for the total group were 10.8 and 0.57,
respectively. Thus, 1 g/dL in albumin represents a larger
change in the scale of the variable than 10 points in
the PCS scale. These findings indicate that a relatively
smaller difference in the PCS scale has a stronger effect
on death and hospitalization than serum albumin con-
centration.
Quality of life is a critically important clinical outcome
for hemodialysis patients. HRQOL measures provide
information about the impact of the treatment on per-
ceived well-being. More attention to the HRQOL instru-
ment (e.g., KDQOL-SF) may help to identify not only
biologic but also psychosocial factors to be the target of
interventions aimed at improving the quality of life of a
specific patient. This study additionally supports the use
of HRQOL measures to identify patients who are at
higher risk of adverse outcomes. Because the present
study is observational, we cannot be sure whether the
association between HRQOL and the outcomes are
causal. Regardless of whether the relationship is causal
or not, the data indicate that HRQOL can serve as a
sensitive indicator of subsequent patient mortality and
morbidity. If the relationship is causal, then interventions
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that can improve HRQOL might also be effective in
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decreasing the risk of mortality and preventing other captured in the MCS and PCS. The results suggest that
the HRQOL measures, particularly PCS, have a greateradverse outcomes in hemodialysis patients.
The associations between lower HRQOL score and capacity to identify patients at greater risk for death and
hospitalization than serum albumin, which has pre-higher risk of adverse outcomes (death and hospitaliza-
tion) were strong and statistically significant, even after viously been recognized as a key marker among dialysis
patients. Moreover, HRQOL seems to predict bothtaking into account albumin and a large number of other
covariates that are known to influence HRQOL, death, shorter-term and longer-term outcomes. Future studies
should assess factors related to change in HRQOL dur-or hospitalization. Thus, it is unlikely that measured con-
founders caused the positive associations. However, ing hemodialysis treatment and the influence of such
changes on the risk of mortality and hospitalization. Itsince approximately 42% of the patients did not fill out
all the questions of KDQOL-SF, we assessed the possi- is also important to assess whether interventions that
improve HRQOL also decrease the risk of death andbility that our results have been partly influenced by
nonresponse bias. The nonresponse rates were approxi- hospitalization among hemodialysis patients.
mately 52%, 32%, and 25% for patients treated in the
United States, Japan, and Europe, respectively. Despite ACKNOWLEDGMENTS
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